Recent Advancements in Machine Learning-Based 1 **Bloodstream Infection Prediction: A Systematic Review** 2 and Meta-analysis of Diagnostic Test Accuracy 3 4 5 Rajeev Bopche, MSc 1* and Jan Kristian Damås, MD, PhD 2,3 6 ¹ Department of Computer Science, Norwegian University of Science and Technology, Trondheim, Norway. 7 ² Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway 8 ³ Department of Infectious Diseases, Clinic of Medicine, St Olavs Hospital, Trondheim, Norway 9 Abstract. 10 Purpose: Bloodstream infections (BSIs) present significant public health challenges. With the advent of machine learning (ML), 11 promising predictive models have been developed. This study evaluates their performance through a systematic review and meta-12 analysis. 13 Methods: We performed a comprehensive systematic review across multiple databases, including PubMed, IEEE Xplore, 14 ScienceDirect, ACM Digital Library, SpringerLink, Web of Science, Scopus, and Google Scholar. Eligible studies focused on 15 BSIs within any hospital setting, employing ML models as the diagnostic test. We evaluated the risk of bias with the Quality 16 Assessment of Diagnostic Accuracy Studies (QUADAS-2) checklist and assessed the quality of evidence using the Grading of 17 Recommendations, Assessment, Development, and Evaluation (GRADE) approach. Models reporting the area under the receiver 18 operating characteristic curve (AUROC) were included in the meta-analysis to identify key performance drivers. 19 Results: After screening, a total of 30 studies were eligible for synthesis, from which 41 models and 8 data types were extracted. 20 Most of the studies were carried out in the inpatient settings (n=17; 56%), followed by the emergency department (ED) settings 21 (n=7; 23%), and followed by the ICU settings (n=6; 20%). The reported AUROCs in the hospital inpatients settings, ranged from 22 0.51-0.866, in the ICU settings AUROCs ranged from 0.668-0.970, and in the emergency department (ED) settings the AUROCs 23 of the models ranged from 0.728-0.844. One study reported prospective cohort study, while two prospectively validated their 24 models. In the meta-analysis, laboratory tests, Complete Blood Count/Differential Count (CBC/DC), and ML model type 25 contributed the most to model performance. 26 Conclusion: This systematic review and meta-analysis show that on retrospective data, individual ML models can accurately 27 predict BSIs at different stages of patient trajectory. Although they enable early prediction of BSI, a comprehensive approach to

¹* Corresponding Author: Rajeev Bopche, rajeev.bopche@ntnu.no

28 integrate data types and models is necessary. Systematic reporting, externally validated, and clinical implementation studies are 29 needed to establish clinical confidence.

Keywords. Bloodstream infection, Machine Learning, Bacteremia, Artificial intelligence, Predictive modelling,
 Sepsis

32 1. INTRODUCTION

33 Bloodstream infections (BSIs) pose a severe public health threat, often escalating to critical conditions such 34 as sepsis and septic shock, particularly if not promptly recognized and treated. The rapid progression of these 35 infections contributes to high morbidity, mortality, and significant healthcare costs, making BSIs a pivotal 36 challenge in clinical care [1, 2]. Currently available clinical decision tools for BSIs and sepsis are primarily 37 based on changes in vital signs and abnormal blood test results, which lack sufficient accuracy [3, 4]. Enhancing 38 prediction capabilities could lead to more efficient resource allocation and cost reduction. Accurate initial 39 stratification helps direct resources to high-risk BSI patients and minimizes unnecessary tests and treatments for 40 those at low risk. Moreover, ambiguous results from blood cultures with contaminants can prolong hospital 41 stays and lead to unnecessary antibiotic administration [5, 6]. Therefore, improving the predictive value of these 42 tests and reducing their unnecessary use are critical for optimizing healthcare resource allocation and 43 minimizing costs.

44

45 Despite the extensive application of machine learning (ML) across various healthcare diagnostics, its 46 potential in BSI prediction has not been fully exploited, particularly when compared to its use in predicting 47 sepsis, where it has been more thoroughly researched [7-14]. This gap underscores a critical oversight; early 48 detection of BSIs can significantly limit their progression to sepsis, thus reducing patient suffering and 49 healthcare expenses [16]. This systematic literature review (SLR) and meta-analysis (MA) seek to bridge this 50 gap by highlighting recent advancements in ML models for BSI prediction. Our analysis spans a range of 51 algorithms and examines the influence of different data types used within these models, providing a 52 comprehensive overview of the current landscape and suggesting directions for future research.

53 1.1. Related works

54 Recent systematic reviews on ML for BSI prediction have illuminated the capabilities of validated models 55 in clinical environments. For example, Eliakim-Raz et al. (2015) emphasize the variability in study populations, 56 model parameters, and validation processes, which highlights the complexity in creating universally effective 57 ML models for BSI prediction [16]. In contrast, the review by Coburn et al. (2012) focuses on the critical 58 clinical and laboratory markers needed to determine the necessity for blood cultures in suspected bacteremia 59 cases, further supporting the role of ML in enhancing diagnostic accuracy and reducing false positives [2]. 60 These studies demonstrate the untapped potential of ML to streamline diagnostic processes and improve patient 61 care in BSI contexts, advocating for its increased integration into BSI prediction strategies.

62 **2. METHODS**

The guidelines provided by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis of
 Diagnostic Test Accuracy studies (PRISMA-DTA) statement [15] was followed for the conduct of this literature
 review and meta-analysis.

66 2.1. Search Strategy

67 The literature search spanned nine databases to cover a wide array of relevant literature. The databases 68 included: PubMed, IEEE Xplore Digital Library, ScienceDirect, ACM Digital Library, SpringerLink, Web of 69 Science, Scopus, and Google Scholar. These databases were selected to encompass a vast range of medical and 70 computer science literature, including journal articles and conference proceedings. To ensure a comprehensive 71 and relevant literature retrieval, we first identified key terms and their possible alternatives. This approach 72 ensures coverage of a broad spectrum of pertinent studies. The core search terms, along with their alternatives, 73 were: Bloodstream Infection (BSI) - Blood culture, Bacteremia, Blood culture test; Prediction - Diagnosis, 74 Identification, Detection; Machine Learning - Artificial Intelligence, Deep Learning, Supervised Learning, 75 Computational Intelligence; Clinical Data - Electronic Health Records (EHR), Electronic Patient Records (EPR), 76 Electronic Medical Records (EMR). Adjustments were made to the query to accommodate the syntax of 77 different database search engines. The search query was constructed by combining these terms using Boolean 78 operators:

80	-	(Bloodstream Infection OR Blood culture OR Bacteremia) AND (Prediction OR Diagnosis OR
81		Identification OR Detection) AND (Machine Learning OR Artificial Intelligence OR Deep Learning
82		OR Supervised Learning OR Computational Intelligence) AND (Clinical Data OR Electronic Health
83		Records OR Electronic Patient Records OR Electronic Medical Records)

84

The selection of relevant studies involved a multi-step process. First, The execution of the search query in each database. Then, Initial screening based on titles and abstracts to exclude non-relevant records. In the third step, detailed screening involving full-text reviews was carried out. The reasons for exclusion were documented. Following this, references in selected articles were examined to identify additional relevant studies, implementing snowballing technique for accessing new literature. This structured approach ensured comprehensive coverage of the topic, allowing the retrieval of documents that met the inclusion criteria for data extraction and analysis to address the research questions of this SLR.

92 **2.2.** Study Selection

93 2.2.1. Inclusion Criteria

- Study Focus: This review specifically targeted studies that utilized machine learning models for the
 prediction of bacteremia, BSI, or positive blood culture results. The primary objective was the
 development or validation of these predictive models.
- 97 Types of Publications: The review was confined to peer-reviewed journal articles and conference
 98 papers.
- 99 **Target Population:** The studies included focused on adult populations.
- Model Specification: Included studies clearly described the ML model(s) used, including the type of
 algorithm, data inputs, and validation methods.
- Outcome Measures: Studies reported specific outcomes related to the accuracy, sensitivity, specificity,
 or predictive value of the ML models for BSI prediction.

104 2.2.2. Exclusion Criteria

Focus on Sepsis and Severe Sepsis: Studies aimed primarily at predicting the onset of sepsis or severe
 sepsis, rather than BSI, were excluded. This was to concentrate on predictive research for BSI, an
 antecedent condition, rather than sepsis, a consequent condition.

108	- Pediatric Studies: Research focusing on neonatal, pediatric, or infant populations was excluded, as the
109	review was limited to adult populations.
110	- Post-Diagnosis Prediction: Studies focusing on predicting outcomes or complications for patients
111	already diagnosed with BSI were excluded. The emphasis was on the initial prediction of BSI.
112	- Non-Machine Learning Models: Research employing statistical or other predictive methodologies
113	without using ML algorithms was not included.
114	- Non-Peer Reviewed Literature: Studies that had not undergone a peer review process, including grey
115	literature, technical reports, and unpublished manuscripts, were excluded.
116	- Opinion Pieces and Theoretical Works: Commentaries, opinion pieces, and purely theoretical works
117	lacking empirical data or validation were omitted.
118	2.2.3. Timeframe and Language Restrictions
119	
120	- Language Restrictions: The review included only studies published in English. This criterion was
121	applied to ensure the feasibility of thorough analysis and comprehension of the research findings.
122	- Timeframe of Publication: The review focused on studies published within the last five years,
123	capturing the most recent advancements in machine learning applications for bloodstream infection
124	prediction.
125	
126	2.3. Data Extraction
127	A structured approach was used to extract relevant data from identified studies. The data extraction process
128	involved the following key elements:
129	- Study Identification: Details including authors, year of publication, and title of the study.
130	- Population Characteristics: Information on the patient demographics, clinical settings, and specific
131	population subgroups studied.
132	- Dataset Description: Description of the dataset used in the study, including size, source, prevalence
133	rates, and period of data collection.
134	- Algorithms Employed: Identification of the specific ML algorithms used in the study.
135	- Reported Metrics : Reporting on the performance metrics used in the study.

- Key Findings and Predictors: Summary of the main findings, including key predictors identified for
 BSI prediction.

138 2.4. Quality Assessment

139 To evaluate risk of bias, we used the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) 140 criteria [17]. Domains included patient selection, index test, reference standard, and flow and timing. In line 141 with the recommendations from the QUADAS-2 guidelines, questions per domain were tailored for this paper 142 and can be found in (Supplementary Information). If one of the questions was scored at risk of bias, the domain 143 was scored as high risk of bias. At least one domain at high risk of bias resulted in an overall score of high risk 144 of bias, only one domain scored as unclear risk of bias resulted in an overall score of unclear risk of bias for that 145 paper. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) 146 methodology to assess the quality of evidence per hospital setting for all studies reporting the area under the 147 curve of the receiver operating characteristic (AUROC) as their performance metric [18]. In line with the 148 GRADE guidelines for diagnostic test accuracy, we included the study design, domains risk of bias (limitations), 149 and inconsistency of the results. One level of evidence was deducted for each domain with serious concerns or 150 high risk of bias, no factors increased the level of evidence (Supplementary Information). Overall level of 151 evidence is expressed in four categories (high, moderate, low, very low).

152 2.5. Meta-analysis

For meta-analysis we conducted univariate and multivariate random effects model analysis fitted using restricted maximum likelihood estimation (REML) for the contribution of covariates towards model performance [19]. We grouped medical data types utilized to train the models such as (demographics as features, vital signs as features, laboratory tests as features, use of textual data, use of time series data, etc.) and included them as covariates. We performed pooled regression analysis to study the most significant covariates per study settings.

159 3. RESULTS

160 **3.1 Study selection**

- 161 A comprehensive literature search was carried out from November 2023 to March 2024, yielding 348 articles
- 162 post-duplication removal. Following an in-depth assessment for eligibility, 30 studies conformed to our
- 163 inclusion criteria, references [20-49]. The selection process, including reasons for exclusion at each stage, is
- 164 outlined in the PRISMA flow diagram (Figure 1). Notably, the majority (29 out of 30) of the included articles
- 165 employed retrospective study designs, with only two conducting prospective validations of their models [40, 41].
- 166 A single study presented a prospective cohort design [29].



167

- 168 Fig. 1 PRISMA flow diagram illustrating the systematic review methodology, depicting the screening, eligibility assessment, and inclusion
- $169 \qquad \text{ of studies, alongside exclusion justifications at each phase} \\$

170 **3.2 Study characteristics**

The studies predominantly took place in inpatient settings (56%, n=17), with the emergency department (ED) (23%, n=7) and intensive care units (ICU) (20%, n=6) also represented. Within inpatient settings, nine studies examined general populations [20-28], and others focused on specific patient cohorts including those with central venous catheters (CVC) [30, 31], systemic inflammatory response syndrome (SIRS) [29], and various other conditions. In ED settings, seven studies were identified [37-43], two of which addressed specific

176	patient groups. ICU-focused research numbered six studies [44-49], again with two concentrating on specific
177	patient subsets. Bacteremia was the primary condition investigated in 24 studies, alongside candidemia and
178	central line-associated bloodstream infection (CLABSI) in others. Contaminants were generally considered
179	negative results, except in two studies [23, 45]. Table 1 presents a synthesis of the study characteristics,
180	including target conditions, patient/sample sizes, data sources, and prevalence, categorized by setting.
181	

182

Table 1. Key characteristics and data sources of selected studies

Setting	First author, year	Target	No.	Data source	Prevalence
		condition	Patients		
Inpatients	Bhavani et al.	Bacteremia	76688	EHRs, University of Chicago Hospital (2008-	Bacteremia 7.7%,
	(2020)	and		2018) and Loyola University Medical Center,	Fungemia 0.7%
		Fungemia		USA (2007-2017)	
	Lee et al. (2019)	Bacteremia	13402	EHRs, Gangnam Severance Hospital, Seoul,	7.9%
				Republic of Korea, (2008-2012)	
	Lee et al. (2022)	Bacteremia	622771*	EHRs, Sinchon and Gangnam Severance	6.2%
				Hospitals, Republic of Korea, (2007-2018)	
	Cheng et al.	Bacteremia	28043	EHRs, Zhengzhou University Hospital, China,	10%
	(2020)			(2017-2018)	
	McFadden et al.	Bacteremia	10965 *	CBC/DC, CPD, Sir Charles Gairdner Hospital,	7.58%
	(2023)			Western Australia (2018-2020)	
	Lien et al. (2022)	Bacteremia	366586 *	EHRs, CBC/DC, Linkou Chang Gung Memorial	8.2%
				Hospital (CGMH) in Taiwan, (2014-2019)	
	Mahmoud et al.	Bacteremia	7157	EHRs, King Abdulaziz Medical City, Riyadh,	11.4%
	(2021)			Saudi Arabia (2017-2019)	
	Garnica et al.	Bacteremia	4357	EHRs, Microbiological data, Hospital	51.3%
	(2021)			Universitario de Fuenlabrada, Madrid, Spain,	
				(2005-2015)	
	Murri et al. (2024)	HA-BSI	5660 *	Generator Center at the Fondazione Policlinico	33.6%
				Universitario A. Gemelli IRCCS (FPG), Rome,	
				Italy (2016-2019)	
Inpatients	Ratzinger et al.	Bacteremia	466	EHRs Vienna General Hospital, Austria, (2011-	28.8%

with SIRS	(2018)			2012)		
Inpatients	Rahmani et al.	CLABSIs	27619	EHRs, a proprietary national longitudinal EHR	1%	
with CVC	(2022)			repository, Houston, Texas, USA (2015-2020)		
	Beeler et al.	CLABSIs	70218 *	EHRs, Indiana University Health Academic	0.6%	
	(2018)			Health Center, USA, (2013-2016)		
HD patients	Zhou et al. (2023)	Bacteremia	391	EHRs, Department of Nephrology, Affiliated	18.9%	
				Hospital of North		
				Sichuan Medical College, Sichuan Province,		
				China, (2018-2022)		
Cancer	Yoo et al. (2021)	Candidemia	34574	EHRs, academic single hospital in Seoul,	0.6%	
patients				Republic of Korea, (2010-2018)		
Maternity	Mooney et al.	Bacteremia	129	CBC parameters, Rotunda Hospital, Ireland	3%	
patients	(2020)			(2019)		
Patients with	Su et al. (2021)	Bacteremia	931	EHRs, Mindong Hospital Affiliated to Fujian	47%	
PCT ≤2.0				Medical University, China, (2014-2020)		
ng/ml						
HIV patients	Wu et al. (2023)	Bacteremia	498	EHRs, Wenzhou Central Hospital, China, (2014-	34.3%	
				2021)		
ED	Choi et al. (2022)	Bacteremia	24768	EHRs, An urban tertiary referral hospital,	12%	
				Republic of Korea, (2016-2018)		
	Choi et al. (2023)	Bacteremia	15362	EHRs, Seoul National University Hospital, Seoul	10.9%	
				National University Bundang Hospital, Republic		
				of Korea, (2016-2018)		
	Boerman et al.	Bacteremia	4885	EHRs, Amsterdam UMC, location VU University	12.2%	
	(2022)			Medical Center, NL, (2018-2020)		
	Chang et al.	Bacteremia	20636	EHRs, CPD, CBC/DC, China Medical University	10.4%	
	(2023)			Hospital, Taiwan, (2021-2022)		
	Schinkel et al.	Bacteremia	6421	EHRs, Amsterdam UMC, (VUMC, AMC, ZMC,	5.4% - 12.3%	
	(2022)			and BIDMC), NL, (2016-2021)		
ED patients	Goh et al. (2022)	Bacteremia	40395	EHRs, National Cheng Kung University Hospital,	10%	
with SIRS				Taiwan, (2015-2019)		
ED patients	Tsai et al. (2023)	Bacteremia	3669	EHRs, Chi Mei Medical Center, Taiwan, (2017-	13.8%	
with fever				2020)		
ICU patients	Roimi et al.	Bacteremia	3372	EHRs, BIDMC, Boston, Massachusetts, USA,	ICU acquired:	
	(2020)			(2008-2012), ICU of Rambam Healthcare	6.4% (BIDMC),	
				Campus (RHCC), Israel, (2013-2017)	15.9% (RHCC)	

	Van Steenkiste et	Bacteremia	2177	EHRs, ICU, Ghent University Hospital, Belgium,	10.5%
	Boner et al.	Bacteremia	6557	EHRs, ICU, University of Virginia, USA, (2011-	13.3%
	(2022)			2015)	
	Pai et al. (2021)	Bacteremia	4275	EHRs, Taichung Veterans General Hospital ICU, Taiwan, (2015-2019)	13.8%
ICU patients with CVC	Parreco et al. (2018)	CLABSIs	57786 *	MIMIC-III database, USA, (2001-2012)	1.5%
ICU patients with new- onset SIRS	Yuan et al. (2021)	Candidemia	7932	EHRs, Peking Union Medical College Hospital, The Affiliated Hospital of Qingdao University, The First Affiliated Hospital of Fujian Medical	1%
				University, China, (2013-2017)	

184

185 Summarizes the salient features and data sources of the selected studies, grouped by the hospital settings

186 Note: * The given number represents the total number of BSI episodes included in the analysis as these studies did not explicitly mention
 187 the number of patients.

188 Most of the reviewed studies were conducted within a single institution; however, three studies utilized 189 datasets encompassing two hospital systems [20, 22, 44], and two studies expanded their analysis to incorporate 190 multi-center data [41, 49]. External validation, which is critical for the generalizability of findings, was 191 performed in four studies [38, 40, 41, 44]. Compliance with the Transparent Reporting of a multivariable 192 prediction model for individual prognosis or diagnosis (TRIPOD) guidelines, which enhance the reliability of 193 predictive modeling, was confirmed in five studies [20, 28, 37, 39, 41, 50]. Data diversity is key in model 194 training and validation. Within this context, three studies utilized the publicly available Medical Information 195 Mart for Intensive Care (MIMIC) database [41, 44, 48], while four studies included Complete Blood 196 Count/Differential Count (CBC/DC) data [24, 25, 34, 40]. Furthermore, two of these studies also incorporated 197 Cell Population Data (CPD) [24, 40], highlighting the integration of detailed hematologic parameters. 198 Unstructured data utilization was observed in one study that utilized textual data [23]. In terms of data 199 accessibility, most studies employed proprietary hospital data. Data sharing policies varied: one study explicitly 200 stated that their data would not be shared [47], one study offered openly available data [34], and ten studies 201 indicated that deidentified data could be provided upon reasonable request [24, 25, 27, 28, 29, 38, 39, 41, 42, 202 49], thus contributing to transparency and reproducibility. Notably, six articles did not specify the number of 203 patients included in their analysis [22, 24, 25, 28, 31, 48].

204 3.3. Models and data types

205 The reported AUROCs in the hospital inpatients settings ranged from 0.51-0.866, while models on select 206 group of participants like HD patients [32], patients with low Procalcitonin (PCT) [35], and HIV patients [36] 207 achieved high AUROCs of 0.91, 0.92, and 0.91 respectively. For the emergency department (ED) settings the 208 AUROCs of the models ranged from 0.728-0.844. For the ICU settings AUROCs ranged from 0.668-0.970. All 209 articles reported high prediction performance (AUROC > 0.7) except for one article [26]. All except two articles 210 [23, 34] reported AUROC as their performance metric. Figure 2 presents a horizontal bar chart that delineates 211 the distribution of AUROC values across the various studies reporting AUROC, with the bar length indicating 212 the range of AUROC values reported across various ML models utilized in the study. The gradient color scheme 213 distinguishes the studies based on the clinical settings, ED (red), inpatient (blue), and ICU (yellow). On the right 214 axis the number of patients, or the number of BC episodes/samples analyzed in the study. Figure 3 depicts the 215 utilization frequency of different ML algorithms categorized into tree-based models, traditional ML algorithms, 216 and neural networks. Notably, tree-based models such as RF and XGB displayed a higher incidence of 217 application. LR was predominantly favored among traditional ML algorithms and within neural networks, ANN 218 and MLP were the commonly employed architectures. Figure 4 presents a horizontal bar graph enumerating the 219 occurrence of various performance metrics in the selected studies. The AUROC was the most reported metric. 220 Figure 5 illustrates the types and diversity of data inputs used with the ML models across the selected studies via 221 a stacked bar chart. The derived risk factors represent the derived clinical features included in the models. The 222 ML algorithms and top predictors for each study grouped by settings are given in Table 2.





Fig. 2 Horizontal bar chart depicting the spread of AUROC values reported in various studies. The studies are listed on the vertical axis, and each bar's horizontal extension represents the range of minimum and maximum AUROC value achieved among the various models employed in the study. The color gradient red, indicates studies in ED, blue, indicating hospital inpatient settings, and the yellow area covers the studies in ICU settings.



234 Fig. 3 Stacked bar chart displaying the occurrence of MLalgorithms in BSI prediction studies across three categories: Tree-based models, 235 Traditional ML Algorithms, and Neural Networks. For Tree-based models: Random Forest (RF), Extreme Gradient Boosting (XGB), 236 Gradient Boosting Machine (GBM), Light Gradient Boosting Machine (LGBM), Extra Trees (ET), Gradient Boosted Trees (GBT), 237 Classification and Regression Trees (CART), and Categorical Boosting (CatBoost). Traditional ML Algorithms include Logistic Regression 238 (LR), Support Vector Machine (SVM), K-Nearest Neighbors (KNN), Decision Tree (DT), Naive Bayes (NB), Generalized Linear Model 239 (GLM), Linear Discriminant Analysis (LDA), Multiple Discriminant Analysis (MDA), and Elastic Net Regression (ENR). Neural Networks 240 are represented by Artificial Neural Network (ANN), Multilayer Perceptron (MLP), Bayesian Neural Network (BNN), Deep Learning (DL), 241 Recurrent Neural Network (RNN), Gated Recurrent Unit (GRU), Convolutional Neural Network (CNN), Bidirectional Long Short-Term 242 Memory (BiLSTM), Attention-based Bidirectional Long Short-Term Memory (ABiLSTM), and Denoising Autoencoder (DAE)



233



- 245 Fig. 4 Horizontal bar graph summarizing the frequency of performance metrics reported in ML studies for BSI prediction. The metrics are
- 246 displayed in descending order of occurrence, starting with Area Under the Receiver Operating Characteristic curve (AUC), followed by
- 247 Sensitivity, Specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV), Accuracy, F1-scores, Area Under the Precision-
- 248 Recall Curve (AUPRC), Precision, Brier scores, Likelihood Ratio (LR), Recall, Akaike Information Criterion (AIC), False Positive Rate
- 249 (FPR), J-Statistic, Cohen's Kappa, F-measure, and Diagnostic Odds Ratio (DOR)



250

251 252

Fig. 5 Stacked bar chart representing the types of data used in machine learning models for predicting bloodstream infections, across various studies listed on the vertical axis. Data types include demographics, vital signs, laboratory tests, textual data, derived risk factors, time-series data, Complete Blood Count/Differential Count (CBC/DC), and Cell Population Data (CPD). Each bar's length indicates the number of data types used in each study, providing a comparison of data diversity across the research

257

258

Table 2. ML algorithms and key predictors in the selected studies

Setting	First author, year	ML models	Key predictors
Inpatients	Bhavani et al.	LR, GBM	Time from admission to BC, Temperature, Age, HR, Prior Bacteremia/Fungemia,

	(2020) [20]		WBC, BUN, Glucose, DBP, SBP, PPI, RR		
	Lee et al. (2019)	MLP, SVM, RF	ALP, PLT, Temperature, SBP, WBC, ICU stay, CRP, CVC, Age, PT, Hospital days to		
	[21]		BC, HR, Gender, Antibiotics, RR, Creatinine		
	Lee et al. (2022)	MLP, RF, XGB	PLT, Monocyte, Neutrophil, Bilirubin, Albumin, and Hospital stay, BUN, ALP, RR,		
	[22]		PR, DBP, TP, WBC, PT, Hb, CRP, Creatinine, ALT, AST, Sodium, Chloride, ESR		
	Cheng et al.	LR, NB, SVM,	Textual chief complaints, Admission records, and Laboratory biochemical indicators.		
	(2020) [23]	ADT, CNN,			
		BiLSTM,			
		ABiLSTM+ DAE			
	McFadden et al.	RF, XGB	CBC, DIFF, and CPD		
	(2023) [24]				
	Lien et al. (2022)	RF, LR	CBC/DC, CRP, and PCT		
	[25]				
	Mahmoud et al.	NN, RF, LR, DT,	Age, Antibiotics use, Surgery within 14 days, CVC, length of hospitalization before		
	(2021) [26]	NB, SVM	BC, RR, SBP, Temperature, DBP, HR, WBC, Sodium, PLT, Albumin, Creatinine,		
			Lactic acid level.		
	Garnica et al.	SVM, RF, KNN	The number of days in ICU before BC extraction, presence of Catheters, Chronic		
	(2021) [27]		Respiratory disease, Fever, Age, CRP, PLT.		
	Murri et al. (2024)	LR	Time BSI > 12 days, Procalcitonin > 1 ng/mL, Presence of a CVC, PLT, Hypotension,		
	[28]		BUN, Presence of urinary catheter, Fever, Tachycardia, Altered mental status, Age,		
. . . .	Det 1	DE ANNI END	Bilirubin, Creatinine		
Inpatients	Ratzinger et al.	KF, ANN, ENK	PC1, LBP, Albumin, Bilirubin		
with SIRS	(2018) [29]				
Inpatients	Rahmani et al.	XGB, DT, LR	Temperature, HGB, comorbidities, Age, WBC, Race, Neutrophil.		
with CVC	(2022) [30]				
	Beeler et al.	RF, LR	Age, Gender, history of CLABSI, CHG (Chlorhexidine Gluconate) Bathing Non-		
	(2018) [31]		compliant Days, Line days.		
HD patients	Zhou et al. (2023)	LR, SVM, DT, RF,	PCT, Temperature, Non-arteriovenous fistula dialysis access, NLR, Leukocyte, dialysis		
	[32]	XGB	duration, LMR, Albumin, Neutrophil, PLT, Age, DBP, CRP, PLR, ALP, SBP, HR,		
~			history of BSI,		
Cancer	Yoo et al. (2021)	LR, ANN, RF,	Variables reflecting the dynamic status of patients with cancer, including blood urea		
patients	[33]	ODIVI, AIVIL	Body weight.		
Maternity	Moonev et al.	CART, LDA, KNN,	NLR, CBC parameters.		
patients	(2020) [34]	SVM, RF			
Patients with	Su et al. (2021)	ANN, KNN. LR.	Interleukin-6, PCT, D-dimer, Lactic acid, Leukocvtes, Neutrophil, and PLT.		
PCT <2 0	[35]	RF, SVM, and NB.	, . , ,,		
ng/ml	[55]				
ng/m					

HIV patients	Wu et al. (2023)	SVM, ANN, GBM,	Low Hb, CD4+T cell, PLT, LDH, BUN, splenomegaly, absence of ART treatment,
	[36]	GLM, MDA, PLR,	Strip shadow, Nodular shadow, and Shock.
		NB, RF	
ED	Choi et al. (2022)	XGB, RF, LR	Chief complaint, Age, Temperature, HR, and DBP at triage stage. Neutrophils, PLT,
	[37]		CRP, Chief complaints, and Creatinine at disposition stage.
	Choi et al. (2023)	BNN	Age, HR, Temperature, DBP, History of chills, Ambulance use
	[38]		
	Boerman et al.	GBT, LR	Bilirubin, Urea, lymphocyte, Pulse rate, CRP, Neutrophil, age, Temperature, DBP,
	(2022) [39]		Potassium, Glucose, Thrombocytes, Creatinine, ALP, SBP, Organ damage
	Chang et al.	CatBoost, LGBM,	Demographics, CPD, CBC/DC
	(2023) [40]	XGB, RF, LR	
	Schinkel et al.	XGB, LR	Temperature, Creatinine, CRP, Lymphocytes, DBP, Bilirubin, Thrombocytes,
	(2022) [41]		Neutrophils, ALP, HR, SBP, Leukocytes, Glucose, Age, Potassium, BUN, Sodium,
			monocytes
ED patients	Goh et al. (2022)	LR, SVM, RF	Age, Gender, COPD, Uncomplicated DM, Hemato-oncology, WBC, Band cell,
with SIRS	[42]		Platelet, Temperature, HR, mild liver disease, Mean arterial pressure, RR, GSC
ED patients	Tsai et al. (2023)	RF, LR, MLP, XGB,	Hypertension, Gender, Temperature, DM, Age, CRP, PLT, WBC, Malignancy,
with fever	[43]	LGBM	Eosinophil, HR, BMI, Hb, RR, SBP, DBP, Band, CKD, Liver Cirrhosis, COPD, GCS
ICU patients	Roimi et al.	RF, XGB	Time duration (days) between sampling time and last defecation, Time duration (hours)
	(2020) [44]		between sampling time and the maximum BUN (mg/dL) value measured during the 5 $$
			days prior to sampling, Length of stay (days) between sampling time and ICU
			admission, The minimal weight (kg) during the 5 days prior to sampling. The time
			duration between sampling time and the maximum MCHC (g/aL) during the 5 days
	Van Staanlinte et	DI STM ANN	Tamparatura Thrambaartas Laukoartas CPD sansis related organ failura assessment
		SVM KNN LR	HR RR PT and mean systemic arterial pressure
	al. (2019) [45]		
	Boner et al.	FNN, GRU, CNN,	Temperature, BUN, BP, HR, Albumin, PLT, Chloride, Creatinine, Chloride, and
	(2022) [46]	LK	Phosphorus.
	Pai et al. (2021)	LR, SVM, MLP, RF,	ALP, CVC period, prothrombin time, PLT, Albumin, Apache II score, Age, foley
	[47]	XGB	
ICU patients	Parreco et al.	LR, GBT, DL	Severity of illness scores (like SAPS II, APS III, and OASIS) and comorbidities.
with CVC	(2018) [48]		
ICU patients	Yuan et al. (2021)	XGB, SVM, RF, ET,	Colonization, Diabetes, AKI, total number of parenteral nutrition days, history of
with new-	[49]	LR	fungal infection, CRRT days, Abdominal surgery, BDG, days of mechanical
onset SIRS			ventilation, Length of hospital and ICU stay, days of CVC

260

261 This table summarizes the ML algorithms and key predictors from the selected studies

262 **3.4. Data challenges and strategies**

263 BSIs may be relatively rare compared to the number of non-infection cases in a dataset. This imbalance can 264 lead models to become biased towards predicting the majority class, reducing their effectiveness in identifying 265 true infection cases. Most studies reported imbalanced dataset with prevalence rates of BSI as given in the Table 266 1. To overcome challenges with data imbalance, Synthetic Minority Over-sampling Technique (SMOTE) was 267 widely used for augmenting the minority class in the dataset by generating synthetic samples [21, 30, 49, 51]. 268 Goh et al. (2022) employed oversampling, undersampling, and random oversampling (ROSE) methods for 269 model development [42]. Lien et al. (2022) and Van Steenkiste et al. (2019) employed Precision-Recall Area 270 Under Curve (PRAUC) metric for a more accurate assessment of model performance in imbalanced datasets [25, 271 45].. The study by Garnica et al. (2021) encountered significant issues with missing data across the patient 272 records used [27]. The types of missing data were classified into three categories: Missing Completely At 273 Random (MCAR), Missing At Random (MAR), and Missing Not At Random (MNAR) [52]. They employed 274 separate class method to represent the missing data, ensuring the ML models could handle these cases without 275 dropping significant amounts of data. Using patient data for training ML models can raise concerns about 276 privacy and data security. Ensuring patient anonymity and complying with regulations can limit the accessibility 277 and use of certain data. Boerman et al. (2022) faced difficulty with the limitation of not being able to use free-278 text data such as physician and nurse reports due to privacy concerns [39]. To ensure patient privacy and 279 compliance with data protection regulations researchers can implement effective deidentification of patient 280 records, involving elimination or alteration of direct identifiers, such as names, age, gender, or location, which 281 could be combined to identify an individual.

282 **3.5. Quality of evidence and risk of bias**

The risk of bias for the retrospective diagnostic test accuracy studies was assessed following the QUADAS-2 guidelines, and the results are shown in Table 3. For patient selection, six articles (20.6%) presented high risk of bias and four articles (13.7%) presented unclear risk of bias for failing to describe the study population and patient selection. For index test 12 articles scored a high risk of bias (41.3%) and five article (17.2%) scored unclear risk of bias, due to non-reporting of data splits and cross-validation strategies. Three articles (10.3%) scored high risk of bias and one score unclear risk of bias for not specifying the reference standards. One article presented unclear risk of bias in the flow and timing.

290

291

Table 3. Risk of Bias Assessment Results According to QUADAS-2 Criteria

Setting	Study	Risk of bias			
		Patient	Index test	Reference	Flow and
		selection		standards	Timing
Inpatients	Bhavani et al. (2020) [20]	Low	Low	Low	Low
	Lee et al. (2019) [21]	Unclear	High	Low	Low
	Lee et al. (2022) [22]	Low	High	Low	Low
	Cheng et al. (2020) [23]	High	High	High	Low
	McFadden et al. (2023)	Low	Low	Low	Low
	[24]				
	Lien et al. (2022) [25]	Low	Unclear	Low	Low
	Mahmoud et al. (2021)	Unclear	High	Low	Low
	[26]				
	Garnica et al. (2021) [27]	Unclear	Low	Low	Low
	Murri et al. (2024) [28]	Low	Low	Low	Low
Inpatients	Rahmani et al. (2022) [30]	Low	High	Low	Low
with CVC	Beeler et al. (2018) [31]	Low	High	Low	Low
Hemodialysis	Zhou et al. (2023) [32]	Unclear	High	Low	Low
patients					
Cancer	Yoo et al. (2021) [33]	Low	Low	Low	Low
patients					
Maternity	Mooney et al. (2020) [34]	Low	Unclear	Low	Low
patients					
Patients with	Su et al. (2021) [35]	High	High	Unclear	Low
procalcitonin					
≤2.0 ng/mL					
HIV patients	Wu et al. (2023) [36]	Low	High	Low	Low
ED patients	Choi et al. (2022) [37]	Low	Low	Low	Low
	Choi et al. (2023) [38]	Low	Low	Low	Low
	Boerman et al. (2022) [39]	Low	Low	Low	Low
	Chang et al. (2023) [40]	Low	Unclear	Low	Low
	Schinkel et al. (2022) [41]	Low	Low	Low	Low
ED patients	Goh et al. (2022) [42]	Low	Unclear	Low	Low

with SIRS					
ED patients	Tsai et al. (2023) [43]	Low	High	Low	Low
with Fever					
ICU patients	Roimi et al. (2020) [44]	Low	Low	Low	Low
	Van Steenkiste et al.	High	High	High	Unclear
	(2019) [45]				
	Boner et al. (2022) [46]	High	Low	High	Low
	Pai et al. (2021) [47]	Low	Unclear	Low	Low
	Parreco et al. (2018) [48]	High	High	Low	Low
ICU patients	Yuan et al. (2021) [49]	High	High	Low	Low
with new-					
onset SIRS					

Assessment of the risk of bias for included studies based on QUADAS-2 criteria, presented by healthcare setting (Inpatients, ED, ICU).
 Columns display the evaluation for patient selection, index test, reference standards, and flow and timing.

294

295 The GRADE evidence profile was estimated by pooling studies based on settings. In this analysis we only 296 considered studies focusing on general adult patient population and did not consider studies reporting specific 297 study population. The GRADE evidence profile is given as Table 4. The studies in ICU and Inpatients settings 298 aggregates were considered at high risk of bias and studies in ED settings aggregates were considered unclear 299 risk of bias. One level of evidence was deducted for observational study design and Inconsistencies due to 300 heterogeneity. Consequently, the quality of evidence for each of the settings was scored as low. Additionally, 301 the outcome column distinguishes AUROC values for high and unclear risk of bias studies. High risk of bias 302 studies reported lowest AUROC values in the inpatient settings and reported highest AUROC values in the ED 303 and ICU settings.

304

Table 4. GRADE Evidence Profile and Quality Assessment of Studies by Setting

Outcome	
AUROC high risk of Quality of	
bias/unclear risk of bias evidence	
0.51-0.762/ 0.74-0.86 Low	

I	ED	5 studies (72,072)	Observational	Unclear risk of bias	Moderate	0.834-0.844/ 0.728-	Low
		[37-41]	cohort studies	(1/5)	heterogeneity	0.782	
	ICU	4 studies (16,381)	Observational	High risk of bias (2/4)	Considerable	0.835-0.97/ 0.668-0.851	Low
		[44-47]	cohort studies		heterogeneity		

305 This table shows the GRADE evidence profile and overall quality of studies segregated by hospital setting (Inpatient, ED, ICU).

306 Note: ^a 4 studies in this pool did not report number of patients and so the reported number of BSI episodes were included to calculate the 307 sum.

308 3.6. Meta-analysis

309 In the meta-analysis, only models presented in articles with target condition bacteremia and general patients 310 population across the three settings were considered. Models for specific disease population, models not 311 reporting AUROC metric, and models predicting CLABSIs were not considered in the meta-analysis. A total of 312 41 models and 9 covariates were included in the meta-analysis. The univariate and multivariate random effect 313 model significant (p-value>0.05) results are shown in Table 5. The random effect model analysis shows that 314 laboratory tests, use of time-series data, use of CBC/DC data, BiLSTM model, XGB model, and RF model 315 positively contributed to the AUROC. We performed a pooled analysis by setting, to identify the best covariates 316 for each. The results of the regression analysis are given as Table 6. For Inpatient setting, demographics 317 (includes age), laboratory tests, and use of CBC/DC data positively contributed to the model performance and 318 use of vital signs negatively impacted the model performance. In contrast in the ICU setting, vital signs, 319 laboratory tests, derived risk factors, use of time-series data, and BiLSTM model employed for sequential data 320 positively impacted the performance metrics.

321

Table 5. Univariate and Multivariate Analysis of Predictive Performance Covariates

Variables	Univariate analysis		Multivariate analysis			
	Coeff	SE	p-value	Coeff	SE	p-value
Vital signs as features	-0.044	0.020	0.034	-0.068	0.012	0.001
Laboratory tests as features	0.211	0.035	0.000			
Time-series data	0.059	0.022	0.012	0.057	0.019	0.001
CBC/DC data	0.195	0.033	0.028			
BiLSTM as model	0.187	0.054	0.001	0.154	0.065	0.000

XGB as model	0.062	0.025	0.024
RF as model	0.052	0.025	0.050

322 This table presents the results of the univariate and multivariate regression analyses identifying the impact of various covariates on the

323 predictive performance of ML models

324

325 Table 6. Pooled Regression Analysis Results by Study Setting

Variables	Regression analysis				
	Coeff	SE	p-value		
Inpatients settings:					
Demographics	0.184	0.010	0.000		
Vitals as features	-0.138	0.010	0.001		
Laboratory features	0.184	0.010	0.000		
CBC/DC data	0.282	0.006	0.000		
ED settings:					
None with significant p-value					
ICU settings:					
Vitals as features	0.131	0.009	0.005		
Laboratory features	0.131	0.009	0.005		
Derived risk factors as features	0.184	0.026	0.020		
Time-series data	0.100	0.024	0.050		
BiLSTM as model	0.250	0.033	0.017		

326 This table presents the coefficients, standard errors, and p-values from the regression analysis of significant covariates affecting model

327 performance in different hospital settings (Inpatient, ED, ICU).

328 4. DISCUSSIONS

This is the first systematic review and meta-analysis that has integrated findings from diverse clinical settings to assess the performance of ML models in predicting BSIs. This work corroborates the growing evidence that ML models are viable tools for enhancing diagnostic accuracy and potentially reducing reliance on

332 traditional blood cultures, a point underscored by contemporary studies [3, 6]. Significantly, our meta-analysis 333 revealed that models performed variably across different clinical environments, with AUROC scores ranging 334 widely. In the inpatient settings, AUROCs ranged from 0.51 to 0.866, demonstrating moderate to high 335 diagnostic accuracy. This performance variance was even more pronounced in the ICU settings, where 336 AUROCs spanned from 0.668 to 0.970, suggesting that certain models are highly effective while others may 337 require further refinement. The variability in model performance aligns with the findings from previous studies 338 which have highlighted the complexity involved in creating universally effective ML models for BSI prediction 339 [16]. This analysis not only validates the potential of ML in clinical diagnostics but also highlights the critical need for tailored approaches depending on specific hospital settings and patient populations. Such 340 341 differentiation in model efficacy emphasizes the importance of context-specific model development and 342 deployment, which should be informed by the distinct dynamics and needs of each clinical environment. 343 Furthermore, the integration of various data types, such as demographic features, laboratory tests, and derived 344 clinical features, has been shown to significantly impact model performance, echoing the findings of recent 345 meta-analyses which advocate for a multi-faceted approach to data integration within ML models to enhance 346 diagnostic precision and reliability [53].

347 **4.1. Clinical relevance and model performance**

348 The findings from our study underscore the potential of ML models to enhance the diagnostic accuracy of 349 bloodstream infections BSIs significantly. This enhancement is crucial, considering the current reliance on 350 traditional blood cultures, which, while standard, are not without their limitations such as delays in results and 351 the potential for contamination [54]. ML models, by leveraging a variety of clinical data, including patient 352 demographics, prior medical history, and laboratory results, can predict BSIs with notable accuracy. This 353 predictive capability is especially valuable in clinical settings where rapid decision-making is critical [55]. By 354 predicting BSIs accurately, ML models can facilitate earlier intervention strategies, potentially leading to 355 improved patient outcomes and reduced mortality rates [56]. Furthermore, the integration of ML into hospital 356 systems offers a pathway to more streamlined resource allocation [57-59]. By accurately identifying patients at 357 high risk of BSIs, hospitals can optimize the use of tests and allocate personnel and medical resources more 358 efficiently [60]. This not only helps in managing hospital resources but also in reducing unnecessary antibiotic 359 use, which is often a knee-jerk response to suspected infections [61].

360 **4.2. Future directions and academic contribution**

361 Our study have laid the groundwork for several promising directions that future investigations could take to 362 advance this critical area of medical informatics. While retrospective studies form the bulk of current research 363 on ML models for BSI prediction, there is a pronounced need for prospective studies. Such studies will allow 364 for real-time data collection and model validation, offering insights that are often obscured in retrospective 365 analyses [12]. This shift could also facilitate the adjustment of models in accordance with dynamic clinical 366 environments, ensuring that they remain robust and reliable over time. The potential of ML models to be 367 integrated into real-time clinical decision support systems represents a significant leap towards operationalizing 368 AI in everyday clinical practice [62]. However, achieving this requires rigorous testing and validation of these 369 models within clinical settings to ensure they perform reliably when interfaced with live data streams [63, 64]. 370 There is substantial scope for exploring new predictive variables that could enhance the predictive accuracy of 371 ML models. The incorporation of genomic data, patient mobility patterns, and real-time monitoring data could 372 provide new insights into infection risk factors, potentially leading to more sophisticated and accurate prediction 373 models [65, 66]. To build trust and validate the efficacy of ML models in clinical settings, systematic reporting 374 and external validation are essential [67, 68]. Models need to be tested across diverse demographics and varied 375 clinical environments to assess their universality and reliability [69-72]. The work of Fleuren et al. (2020) and 376 Moor et al. (2021) highlights the importance of such validation in confirming the utility and accuracy of 377 predictive models for sepsis, which can be paralleled in BSI prediction [12, 13]. As ML applications in 378 healthcare continue to expand, it is crucial to consider the regulatory and ethical implications of their use [73, 379 74]. Ensuring patient privacy, securing data, and maintaining transparency in AI decision-making processes are 380 paramount [75, 76]. Future research must also address these aspects to foster a safe and trustful adoption of AI 381 technologies in healthcare.

382 4.2. Strengths and Limitations

Our systematic review and meta-analysis are grounded in a comprehensive, methodologically robust approach that integrates a variety of data sources and analytical techniques. The extensive database search across multiple platforms including PubMed, IEEE Xplore, and Scopus ensures a broad capture of relevant studies, reducing the risk of publication bias. This wide-ranging data acquisition is supplemented by our application of the QUADAS-2 framework and GRADE methodology, which enhances the credibility of our

388 findings by systematically assessing the risk of bias and the quality of evidence across studies. Furthermore, the 389 synthesis of data into figures and comprehensive tables enables clear visual representation and understanding of 390 the applications of ML models across varied clinical settings. Our findings are supported by rigorous statistical 391 analysis, including univariate and multivariate models, which reveal key performance drivers and validate the 392 predictive power of ML models for bloodstream infections. Despite these strengths, several limitations must be 393 acknowledged. A significant proportion of the included studies utilized retrospective designs. While 394 retrospective studies provide valuable historical insights, they are inherently limited by the data available, often 395 lacking the prospective validation needed to confirm the efficacy of predictive models under current clinical 396 conditions. This design limitation impacts the generalizability of our findings, as the models might perform 397 differently when deployed in real-time environments. To enhance the generalizability and applicability of future 398 research, several strategies can be adopted. Prospective study designs should be prioritized, as they allow for the 399 real-time evaluation and adjustment of ML models, ensuring that the models are tested and validated under 400 varied clinical conditions. This approach not only tests the robustness of the models but also helps in fine-tuning 401 them for practical deployment. Furthermore, multi-center studies involving diverse populations and settings 402 should be encouraged to test the efficacy of these predictive models across different demographics and 403 operational conditions. Such studies can help identify and mitigate any population-specific biases, thereby 404 enhancing the models' applicability and reliability. Lastly, ongoing validation and systematic reporting should 405 be integral to future research efforts. By continuously assessing and reporting the performance of ML models, 406 researchers can ensure that these tools remain effective and relevant in the ever-evolving clinical landscape. By 407 addressing these limitations and building on the strengths of our current approach, future research can 408 significantly advance the field of ML in medical diagnostics, particularly in the prediction and management of 409 bloodstream infections.

410 **5. CONCLUSIONS**

411 Our systematic review and meta-analysis have critically evaluated the efficacy of ML models in predicting 412 BSIs, a crucial domain where timely and accurate diagnosis can significantly influence clinical outcomes. ML 413 models, especially those incorporating diverse data types such as laboratory results and demographic 414 information, demonstrated a capacity to predict BSIs with a high degree of accuracy. The integration of these 415 models into clinical settings can potentially reduce the reliance on traditional blood cultures, which, while

416	foundational, are hampered by delays and susceptibility to contamination. This shift could streamline diagnostic
417	workflows and enhance the speed and precision of infection response interventions, thus improving patient care
418	and outcomes. To advance the use of ML in predicting BSIs, future research should focus on prospective studies
419	and the development of real-time, adaptive ML systems that can be integrated seamlessly into clinical decision-
420	support frameworks. Furthermore, external validation of these models across diverse populations and settings is
421	essential to bolster clinical confidence and foster wider adoption. In conclusion, while ML models hold
422	significant promise for transforming BSI diagnosis, their successful implementation will depend on meticulous
423	model development, validation, and customization tailored to the nuanced demands of different healthcare
424	settings. This holistic approach will be crucial in overcoming the current challenges and fully realizing the
425	potential of ML in clinical diagnostics.
426	Acknowledgements
127	We would like to thank the researchers at Mid Nerway Centre for Sancis Desearch for valuable discussions and
427	fandbaak
420	iceuback.
420	Author's contributions
431	
432	RB conceptualized and designed the study with inputs from IKD and ØN RB performed database search and
433	literature analysis RB wrote the initial and subsequent drafts of the manuscript, which other authors reviewed
434	and approved.
435	
436	Funding
437	Financial support for this study was provided by the Computational Sepsis Mining and Modelling project
438	through the Norwegian University of Science and Technology Health Strategic Area.
439	
440	Appendix: List of Medical Abbreviations
441	ALP: Alkaline Phosphatase

• ALT: Alanine Aminotransferase

443	•	APS III: Acute Physiology Score III
444	•	ART: Antiretroviral Therapy
445	•	AST: Aspartate Aminotransferase
446	•	AKI: Acute Kidney Injury
447	•	BC: Blood Cultures
448	•	BDG: Beta-D-Glucan
449	•	BUN: Blood Urea Nitrogen
450	•	CBC: Complete Blood Count
451	•	CHG: Chlorhexidine Gluconate
452	•	CKD: Chronic Kidney Disease
453	•	CLABSI: Central Line-Associated Bloodstream Infection
454	•	COPD: Chronic Obstructive Pulmonary Disease
455	•	CPD: Cephalopelvic Disproportion
456	•	CRP: C-reactive Protein
457	•	CRRT: Continuous Renal Replacement Therapy
458	•	CVC: Central Venous Catheter
459	•	DBP: Diastolic Blood Pressure
460	•	DIFF: Differential Count
461	•	DM: Diabetes Mellitus
462	•	ESR: Erythrocyte Sedimentation Rate
463	•	GCS: Glasgow Coma Scale
464	•	Hb: Hemoglobin
465	•	HR: Heart Rate
466	•	ICU: Intensive Care Unit
467	•	LMR: Lymphocyte to Monocyte Ratio
468	•	NLR: Neutrophil to Lymphocyte Ratio
469	•	OASIS: Oxford Acute Severity of Illness Score
470	•	PCT: Procalcitonin
471	•	PLR: Platelet to Lymphocyte Ratio

472	PLT: Platelet Count
473	PPI: Proton Pump Inhibitor
474	• PT: Prothrombin Time
475	RR: Respiratory Rate
476	SAPS II: Simplified Acute Physiology Score II
477	SBP: Systolic Blood Pressure
478	WBC: White Blood Cell Count
479	
480	References
481	
401	
482	[1] Goto, M., & Al-Hasan, M. N. (2013). Overall burden of bloodstream infection and nosocomial bloodstream infection in North America
483	and Europe. Clinical Microbiology and Infection, 19(6), 501-509. https://doi.org/10.1111/1469-0691.12195
484	[2] Coburn, B., Morris, A. M., Tomlinson, G., & Detsky, A. S. (2012). Does this adult patient with suspected bacteremia require blood
485	cultures?. JAMA, 308(5), 502-511. https://doi.org/10.1001/jama.2012.8262
486	[3] Wong A, Otles E, Donnelly JP, et al. External Validation of a Widely Implemented Proprietary Sepsis Prediction Model in Hospitalized
487	Patients. JAMA Intern Med. 2021;181(8):1065-1070. doi:10.1001/jamainternmed.2021.2626
488	[4] Schootman, M., Wiskow, C., Loux, T., Meyer, L., Powell, S., Gandhi, A., & Lacasse, A. (2022). Evaluation of the effectiveness of an
489	automated sepsis predictive tool on patient outcomes. Journal of critical care, 71, 154061. https://doi.org/10.1016/j.jcrc.2022.154061
490	[5] Bates, D. W., Cook, E. F., Goldman, L., & Lee, T. H. (1990). Predicting bacteremia in hospitalized patients. A prospectively validated
491	model. Annals of internal medicine, 113(7), 495-500. https://doi.org/10.7326/0003-4819-113-7-495
492	[6] Sakarikou, C., Altieri, A., Bossa, M. C., Minelli, S., Dolfa, C., Piperno, M., & Favalli, C. (2018). Rapid and cost-effective identification
493	and antimicrobial susceptibility testing in patients with Gram-negative bacteremia directly from blood-culture fluid. Journal of
494	microbiological methods, 146, 7-12. https://doi.org/10.1016/j.mimet.2018.01.012
495	[7] Buch, V. H., Ahmed, I. & Maruthappu, M. Artificial intelligence in medicine: Current trends and future possibilities. Br. J. Gen. Pract. 68, 143-
496	144. https://doi.org/10.3399/bjgp1 8X695 213 (2018).
497	[8] Rajpurkar, P., Chen, E., Banerjee, O. et al. AI in health and medicine. Nat Med 28, 31–38 (2022). https://doi.org/10.1038/s41591-021-
498	<u>01614-0</u>
499	[9] A. Baldominos, A. Puello, H. Oğul, T. Aşuroğlu and R. Colomo-Palacios, "Predicting Infections Using Computational Intelligence - A
500	Systematic Review," in IEEE Access, vol. 8, pp. 31083-31102, 2020, doi: 10.1109/ACCESS.2020.2973006.
501	[10] Hassan, N., Slight, R., Weiand, D., Vellinga, A., Morgan, G., Aboushareb, F., & Slight, S. P. (2021). Preventing sepsis; how can
502	artificial intelligence inform the clinical decision-making process? A systematic review. International journal of medical informatics,
503	150, 104457. https://doi.org/10.1016/j.ijmedinf.2021.104457
504	[11] Islam, K. R., Prithula, J., Kumar, J., Tan, T. L., Reaz, M. B. I., Sumon, M. S. I., & Chowdhury, M. E. H. (2023). Machine Learning-
505	Based Early Prediction of Sepsis Using Electronic Health Records: A Systematic Review. Journal of clinical medicine, 12(17), 5658.
506	https://doi.org/10.3390/jcm12175658

- 507 [12] Fleuren, L. M., Klausch, T. L. T., Zwager, C. L., Schoonmade, L. J., Guo, T., Roggeveen, L. F., Swart, E. L., Girbes, A. R. J., Thoral,
- 508 P., Ercole, A., Hoogendoorn, M., & Elbers, P. W. G. (2020). Machine learning for the prediction of sepsis: a systematic review and
- 509 meta-analysis of diagnostic test accuracy. Intensive care medicine, 46(3), 383–400. https://doi.org/10.1007/s00134-019-05872-y
- 510 [13] Moor, M., Rieck, B., Horn, M., Jutzeler, C. R., & Borgwardt, K. (2021). Early Prediction of Sepsis in the ICU Using Machine
 511 Learning: A Systematic Review. *Frontiers in medicine*, 8, 607952. <u>https://doi.org/10.3389/fmed.2021.607952</u>
- 512 [14] Deng, H. F., Sun, M. W., Wang, Y., Zeng, J., Yuan, T., Li, T., Li, D. H., Chen, W., Zhou, P., Wang, Q., & Jiang, H. (2021).
 513 Evaluating machine learning models for sepsis
- 514 [15] McInnes, M. D. F., Moher, D., Thombs, B. D., McGrath, T. A., Bossuyt, P. M., and the PRISMA-DTA Group, Clifford, T., Cohen, J.
- 515 F., Deeks, J. J., Gatsonis, C., Hooft, L., Hunt, H. A., Hyde, C. J., Korevaar, D. A., Leeflang, M. M. G., Macaskill, P., Reitsma, J. B.,
- 516 Rodin, R., Rutjes, A. W. S., Salameh, J. P., ... Willis, B. H. (2018). Preferred Reporting Items for a Systematic Review and Meta-
- 517 analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA, 319(4), 388–396.
 518 <u>https://doi.org/10.1001/jama.2017.19163</u>
- Eliakim-Raz, N., Bates, D. W., & Leibovici, L. (2015). Predicting bacteraemia in validated models--a systematic review. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 21(4),
 295–301. <u>https://doi.org/10.1016/j.cmi.2015.01.023</u>
- 522 [17] Whiting PF, Rutjes AWS, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy
 523 studies. Ann Intern Med 155:529. https://doi.org/10.7326/0003-4819-155-8-201110180-00009
- 524 [18] Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Jr, Kunz, R., Craig, J., Montori,
 525 V. M., Bossuyt, P., Guyatt, G. H., & GRADE Working Group (2008). Grading quality of evidence and strength of recommendations
- 526 for diagnostic tests and strategies. BMJ (Clinical research ed.), 336(7653), 1106–1110. <u>https://doi.org/10.1136/bmj.39500.677199.AE</u>
- 527 [19] Higgins, J. P., Thompson, S. G., & Spiegelhalter, D. J. (2009). A re-evaluation of random-effects meta-analysis. Journal of the Royal
 528 Statistical Society. Series A, (Statistics in Society), 172(1), 137–159. https://doi.org/10.1111/j.1467-985X.2008.00552.x
- 529 [20] Bhavani, S. V., Lonjers, Z., Carey, K. A., Afshar, M., Gilbert, E. R., Shah, N. S., Huang, E. S., & Churpek, M. M. (2020). The
 530 Development and Validation of a Machine Learning Model to Predict Bacteremia and Fungemia in Hospitalized Patients Using
- 531 Electronic Health Record Data. Critical Care Medicine, 48(11), E1020–E1028. https://doi.org/10.1097/CCM.00000000004556
- [21] Lee, K. H., Dong, J. J., Jeong, S. J., Chae, M.-H., Lee, B. S., Kim, H. J., Ko, S. H., & Song, Y. G. (2019). Early detection of
 bacteraemia using ten clinical variables with an artificial neural network approach. *Journal of Clinical Medicine*, 8(10).
 https://doi.org/10.3390/jcm8101592
- 535 [22] Lee, K. H., Dong, J. J., Kim, S., Kim, D., Hyun, J. H., Chae, M.-H., Lee, B. S., & Song, Y. G. (2022). Prediction of Bacteremia Based
 536 on 12-Year Medical Data Using a Machine Learning Approach: Effect of Medical Data by Extraction Time. *Diagnostics*, *12*(1).
 537 https://doi.org/10.3390/diagnostics12010102
- 538 [23] Cheng, M., Zhao, X., Ding, X., Gao, J., Xiong, S., & Ren, Y. (2020). Prediction of blood culture outcome using hybrid neural network
 539 model based on electronic health records. BMC medical informatics and decision making, 20(Suppl 3), 121.

540 https://doi.org/10.1186/s12911-020-1113-4

- 541 [24] McFadden, B. R., Inglis, T. J. J., & Reynolds, M. (2023). Machine learning pipeline for blood culture outcome prediction using
 542 Sysmex XN-2000 blood sample results in Western Australia. *BMC Infectious Diseases*, 23(1). <u>https://doi.org/10.1186/s12879-023-</u>
- 543 <u>08535-y</u>

- 544 [25] Lien, F., Lin, H.-S., Wu, Y.-T., & Chiueh, T.-S. (2022). Bacteremia detection from complete blood count and differential leukocyte
- count with machine learning: complementary and competitive with C-reactive protein and procalcitonin tests. *BMC Infectious Diseases*, 22(1). <u>https://doi.org/10.1186/s12879-022-07223-7</u>
- 547 [26] Mahmoud, E., Dhoayan, M. A., Bosaeed, M., al Johani, S., & Arabi, Y. M. (2021). Developing machine-learning prediction algorithm
- 548 for bacteremia in admitted patients. Infection and Drug Resistance, 14, 757–765. https://doi.org/10.2147/IDR.S293496
- 549 [27] Garnica, O., Gómez, D., Ramos, V., Hidalgo, J. I., & Ruiz-Giardín, J. M. (2021). Diagnosing hospital bacteraemia in the framework of 550 predictive, preventive and personalised medicine using electronic health records and machine learning classifiers. *EPMA Journal*,
- 551 *12*(3), 365–381. <u>https://doi.org/10.1007/s13167-021-00252-3</u>
- 552 [28] Murri, R., De Angelis, G., Antenucci, L., Fiori, B., Rinaldi, R., Fantoni, M., Damiani, A., Patarnello, S., Sanguinetti, M., Valentini, V.,
- Posteraro, B., & Masciocchi, C. (2024). A Machine Learning Predictive Model of Bloodstream Infection in Hospitalized Patients.
 Diagnostics (Basel, Switzerland), 14(4), 445. <u>https://doi.org/10.3390/diagnostics14040445</u>
- 555 [29] Ratzinger, F., Haslacher, H., Perkmann, T., Pinzan, M., Anner, P., Makristathis, A., Burgmann, H., Heinze, G., & Dorffner, G. (2018).
- Machine learning for fast identification of bacteraemia in SIRS patients treated on standard care wards: a cohort study. *Scientific Reports*, 8(1). https://doi.org/10.1038/s41598-018-30236-9
- [30] Rahmani, K., Garikipati, A., Barnes, G., Hoffman, J., Calvert, J., Mao, Q., & Das, R. (2022). Early prediction of central line associated
 bloodstream infection using machine learning. American journal of infection control, 50(4), 440–445.
 https://doi.org/10.1016/j.ajic.2021.08.017
- [31] Beeler, C., Dbeibo, L., Kelley, K., Thatcher, L., Webb, D., Bah, A., Monahan, P., Fowler, N. R., Nicol, S., Judy-Malcolm, A., Judy Malcolm, A., & Azar, J. (2018). Assessing patient risk of central line-associated bacteremia via machine learning. *American Journal* of Infection Control, 46(9), 986–991. https://doi.org/10.1016/j.ajic.2018.02.021
- [32] Zhou, T., Ren, Z., Ma, Y., He, L., Liu, J., Tang, J., & Zhang, H. (2023). Early identification of bloodstream infection in hemodialysis
 patients by machine learning. *Heliyon*, 9(7). https://doi.org/10.1016/j.heliyon.2023.e18263
- [33] Yoo, J., Kim, S. H., Hur, S., Ha, J., Huh, K., & Cha, W. C. (2021). Candidemia Risk Prediction (CanDETEC) Model for Patients With
 Malignancy: Model Development and Validation in a Single-Center Retrospective Study. JMIR medical informatics, 9(7), e24651.
 https://doi.org/10.2196/24651
- [34] Mooney, C., Eogan, M., Ní Áinle, F., Cleary, B., Gallagher, J. J., O'Loughlin, J., & Drew, R. J. (2021). Predicting bacteraemia in
 maternity patients using full blood count parameters: A supervised machine learning algorithm approach. *International Journal of Laboratory Hematology*, 43(4), 609–615. https://doi.org/10.1111/ijlh.13434
- 572 [35] Su, M., Chen, H., Qiu, J., & Huang, J. (2021). Four Biomarkers-Based Artificial Neural Network Model for Accurate Early Prediction
 573 of Bacteremia with Low-level Procalcitonin. *Annals of Clinical and Laboratory Science*, 51(3), 408–414.
- 574 [36] Wu, L., Xia, D., & Xu, K. (2023). Multi-Clinical Factors Combined with an Artificial Intelligence Algorithm Diagnosis Model for
- 575 HIV-Infected People with Bloodstream Infection. Infection and Drug Resistance, 16, 6085–6097.
 576 https://doi.org/10.2147/IDR.S423709
- 577 [37] Choi, D. H., Hong, K. J., Park, J. H., Shin, S. D., Ro, Y. S., Song, K. J., Kim, K. H., & Kim, S. (2022). Prediction of bacteremia at the
- 578 emergency department during triage and disposition stages using machine learning models. *American Journal of Emergency Medicine*,
- 579 53, 86–93. https://doi.org/10.1016/j.ajem.2021.12.065

- 580 [38] Choi, D. H., Lim, M. H., Kim, K. H., Shin, S. D., Hong, K. J., & Kim, S. (2023). Development of an artificial intelligence bacteremia
- 581 prediction model and evaluation of its impact on physician predictions focusing on uncertainty. Scientific Reports, 13(1). 582 https://doi.org/10.1038/s41598-023-40708-2
- 583 [39] Boerman, A. W., Schinkel, M., Meijerink, L., van den Ende, E. S., Pladet, L. C., Scholtemeijer, M. G., Zeeuw, J., van der Zaag, A. Y.,
- 584 Minderhoud, T. C., Elbers, P. W. G., Wiersinga, W. J., de Jonge, R., Kramer, M. H., & Nanayakkara, P. W. B. (2022). Using machine 585 learning to predict blood culture outcomes in the emergency department: a single-centre, retrospective, observational study. BMJ open, 586
- 12(1), e053332. https://doi.org/10.1136/bmjopen-2021-053332
- 587 [40] Chang, Y.-H., Hsiao, C.-T., Chang, Y.-C., Lai, H.-Y., Lin, H.-H., Chen, C.-C., Hsu, L.-C., Wu, S.-Y., Shih, H.-M., Hsueh, P.-R., 588 Hsueh, P.-R., & Cho, D.-Y. (2023). Machine learning of cell population data, complete blood count, and differential count parameters 589 for early prediction of bacteremia among adult patients with suspected bacterial infections and blood culture sampling in emergency
- 590 departments. Journal of Microbiology, Immunology and Infection, 56(4), 782-792. https://doi.org/10.1016/j.jmii.2023.05.001
- 591 [41] Schinkel, M., Boerman, A. W., Bennis, F. C., Minderhoud, T. C., Lie, M., Peters-Sengers, H., Holleman, F., Schade, R. P., de Jonge,
- 592 R., Wiersinga, W. J., Wiersinga, W. J., & Nanayakkara, P. W. B. (2022). Diagnostic stewardship for blood cultures in the emergency 593 department: A multicenter validation and prospective evaluation of a machine learning prediction tool. EBioMedicine, 82. 594 https://doi.org/10.1016/j.ebiom.2022.104176
- 595 [42] Goh, V., Chou, Y.-J., Lee, C.-C., Ma, M.-C., Wang, W. Y. C., Lin, C.-H., & Hsieh, C.-C. (2022). Predicting Bacteremia among Septic 596 Patients Based on ED Information by Machine Learning Methods: A Comparative Study. Diagnostics, 12(10). 597 https://doi.org/10.3390/diagnostics12102498
- 598 [43] Tsai, W.-C., Liu, C.-F., Ma, Y.-S., Chen, C.-J., Lin, H.-J., Hsu, C.-C., Chow, J. C., Chien, Y.-W., & Huang, C.-C. (2023). Real-time 599 artificial intelligence system for bacteremia prediction in adult febrile emergency department patients. International Journal of 600 Medical Informatics, 178. https://doi.org/10.1016/j.ijmedinf.2023.105176
- 601 [44] Roimi, M., Neuberger, A., Shrot, A., Paul, M., Geffen, Y., & Bar-Lavie, Y. (2020). Early diagnosis of bloodstream infections in the 602 intensive care unit using machine-learning algorithms. Intensive Care Medicine, 46(3), 454-462. https://doi.org/10.1007/s00134-019-603 05876-8
- 604 [45] Van Steenkiste, T., Ruyssinck, J., De Baets, L., Decruyenaere, J., De Turck, F., Ongenae, F., & Dhaene, T. (2019). Accurate 605 prediction of blood culture outcome in the intensive care unit using long short-term memory neural networks. Artificial intelligence in 606 medicine, 97, 38-43. https://doi.org/10.1016/j.artmed.2018.10.008
- 607 [46] Boner, Z., & Moore, C. C. (2022). Deep Learning Risk Prediction of Bloodstream Infection in the Intensive Care Unit. In KDD 608 Undergraduate Consortium, August 14-18, 2022, Washington, D.C... ACM, New York, NY, USA, 7 pages
- 609 [47] Pai, K.-C., Wang, M.-S., Chen, Y.-F., Tseng, C.-H., Liu, P.-Y., Chen, L.-C., Sheu, R.-K., & Wu, C.-L. (2021). An artificial 610 intelligence approach to bloodstream infections prediction. Journal of Clinical Medicine, 10(13). https://doi.org/10.3390/jcm10132901
- 611 [48] Parreco, J. P., Hidalgo, A. E., Badilla, A. D., Ilyas, O., & Rattan, R. (2018). Predicting central line-associated bloodstream infections
- 612 and mortality using supervised machine learning. Journal of Critical Care, 45, 156-162. https://doi.org/10.1016/j.jcrc.2018.02.010
- 613 [49] Yuan, S., Sun, Y., Xiao, X., Long, Y., & He, H. (2021). Using Machine Learning Algorithms to Predict Candidaemia in ICU Patients
- 614 With New-Onset Systemic Inflammatory Response Syndrome. Frontiers in Medicine, 8. https://doi.org/10.3389/fmed.2021.720926

- 615 [50] Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. (2015). Transparent reporting of a multivariable prediction model for
- 616 individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ (Clinical research ed.), 350, g7594.
- 617 <u>https://doi.org/10.1136/bmj.g7594</u>
- 618 [51] Chawla, N. V., Bowyer, K. W., Hall, L. O., & Kegelmeyer, W. P. (2002). SMOTE: synthetic minority over-sampling technique.
- 619Journal of artificial intelligence research, 16, 321-357.
- 620 [52] Little, R., & Rubin, D. (2019). Statistical analysis with missing data, third edition. Wiley.
- 621 [53] Younis HA, Eisa TAE, Nasser M, et al. A Systematic Review and Meta-Analysis of Artificial Intelligence Tools in Medicine and
- Healthcare: Applications, Considerations, Limitations, Motivation and Challenges. Diagnostics (Basel). 2024;14(1):109. Published
 2024 Jan 4. doi:10.3390/diagnostics14010109
- 624 [54] Dargère, S., Cormier, H., & Verdon, R. (2018). Contaminants in blood cultures: importance, implications, interpretation and
- 625 prevention. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and
- 626 Infectious Diseases, 24(9), 964–969. <u>https://doi.org/10.1016/j.cmi.2018.03.030</u>
- 627 [55] Habehh, H., & Gohel, S. (2021). Machine Learning in Healthcare. Current genomics, 22(4), 291–300.
- 628 https://doi.org/10.2174/1389202922666210705124359
- 629 [56] Zoabi, Y., Kehat, O., Lahav, D. et al. Predicting bloodstream infection outcome using machine learning. Sci Rep 11, 20101 (2021).
- 630 https://doi.org/10.1038/s41598-021-99105-2
- 631 [57] Bohr, A., & Memarzadeh, K. (2020). The rise of artificial intelligence in healthcare applications. Artificial Intelligence in Healthcare,
 632 25–60. https://doi.org/10.1016/B978-0-12-818438-7.00002-2
- [58] Javaid, M., Haleem, A., Singh, R. P., Suman, R., & Rab, S. (2022). Significance of machine learning in healthcare: Features, pillars
 and applications. International Journal of Intelligent Networks, 3, 58-73. https://doi.org/10.1016/j.ijin.2022.05.002
- 635 [59] Bajwa, J., Munir, U., Nori, A., & Williams, B. (2021). Artificial intelligence in healthcare: transforming the practice of medicine.
- 636 Future healthcare journal, 8(2), e188–e194. <u>https://doi.org/10.7861/fhj.2021-0095</u>
- 637 [60] Batko, K., & Ślęzak, A. (2022). The use of Big Data Analytics in healthcare. Journal of big data, 9(1), 3.
- 638 https://doi.org/10.1186/s40537-021-00553-4
- 639 [61] Alemkere, G., Tenna, A., & Engidawork, E. (2019). Antibiotic use practice and predictors of hospital outcome among patients with
- 640 systemic bacterial infection: Identifying targets for antibiotic and health care resource stewardship. PloS one, 14(2), e0212661.
- 641 https://doi.org/10.1371/journal.pone.0212661
- 642 [62] Giordano, C., Brennan, M., Mohamed, B., Rashidi, P., Modave, F., & Tighe, P. (2021). Accessing Artificial Intelligence for Clinical
 643 Decision-Making. Frontiers in digital health, 3, 645232. https://doi.org/10.3389/fdgth.2021.645232
- 644 [63] Antoniadi AM, Du Y, Guendouz Y, Wei L, Mazo C, Becker BA, Mooney C. Current Challenges and Future Opportunities for XAI in
- 645 Machine Learning-Based Clinical Decision Support Systems: A Systematic Review. Applied Sciences. 2021; 11(11):5088.
- 646 https://doi.org/10.3390/app11115088
- 647 [64] Susanto, A. P., Lyell, D., Widyantoro, B., Berkovsky, S., & Magrabi, F. (2024). How Well Do AI-Enabled Decision Support Systems
 648 Perform in Clinical Settings?. Studies in health technology and informatics, 310, 279–283. <u>https://doi.org/10.3233/SHTI230971</u>
- 649 [65] Iqbal, J., Cortés Jaimes, D. C., Makineni, P., Subramani, S., Hemaida, S., Thugu, T. R., Butt, A. N., Sikto, J. T., Kaur, P., Lak, M. A.,
- 650 Augustine, M., Shahzad, R., & Arain, M. (2023). Reimagining Healthcare: Unleashing the Power of Artificial Intelligence in Medicine.
- 651 Cureus, 15(9), e44658. <u>https://doi.org/10.7759/cureus.44658</u>

- 652 [66] Xu, Y., Liu, X., Cao, X., Huang, C., Liu, E., Qian, S., Liu, X., Wu, Y., Dong, F., Qiu, C.-W., Qiu, J., Hua, K., Su, W., Wu, J., Xu, H.,
- Han, Y., Fu, C., Yin, Z., Liu, M., Roepman, R., ... Zhang, J. (2021). Artificial intelligence: A powerful paradigm for scientific research.
- 654 The Innovation, 2(4), Article 100179. <u>https://doi.org/10.1016/j.xinn.2021.100179</u>
- 655 [67] Myllyaho, L., Raatikainen, M., Männistö, T., Mikkonen, T., & Nurminen, J. K. (2021). Systematic literature review of validation
- 656 methods for AI systems. Journal of Systems and Software, 181, Article 111050. https://doi.org/10.1016/j.jss.2021.111050
- 657 [68] de Hond, A.A.H., Leeuwenberg, A.M., Hooft, L. et al. Guidelines and quality criteria for artificial intelligence-based prediction
- models in healthcare: a scoping review. npj Digit. Med. 5, 2 (2022). <u>https://doi.org/10.1038/s41746-021-00549-7</u>
- 659 [69] Stevens, L. M., Mortazavi, B. J., Deo, R. C., Curtis, L., & Kao, D. P. (2020). Recommendations for Reporting Machine Learning
- 660 Analyses in Clinical Research. Circulation. Cardiovascular quality and outcomes, 13(10), e006556.
- 661 https://doi.org/10.1161/CIRCOUTCOMES.120.006556
- 662 [70] Rieke, N., Hancox, J., Li, W. et al. The future of digital health with federated learning. npj Digit. Med. 3, 119 (2020).
- 663 <u>https://doi.org/10.1038/s41746-020-00323-1</u>
- 664 [71] Moor, M., Banerjee, O., Abad, Z.S.H. et al. Foundation models for generalist medical artificial intelligence. Nature 616, 259–265
- 665 (2023). <u>https://doi.org/10.1038/s41586-023-05881-4</u>
- 666 [72] Antoniou, T., & Mamdani, M. (2021). Evaluation of machine learning solutions in medicine. CMAJ : Canadian Medical Association
- journal = journal de l'Association medicale canadienne, 193(36), E1425–E1429. <u>https://doi.org/10.1503/cmaj.210036</u>
- 668 [73] Gerke, S., Minssen, T., & Cohen, G. (2020). Ethical and legal challenges of artificial intelligence-driven healthcare. Artificial
 669 Intelligence in Healthcare, 295–336. https://doi.org/10.1016/B978-0-12-818438-7.00012-5
- 670 [74] Naik, N., Zeeshan, H. B. M., Shetty, D. K., Swain, D., Shah, M., Paul, R., Aggarwal, K., Ibrahim, S., Patil, V., Komal, S., Shetty, S.,
- 671 Rai, B. P., Chlosta, P., & Somani, B. K. (2022). Legal and ethical consideration in artificial intelligence in healthcare: Who takes

672 responsibility? Frontiers in Surgery, 9. <u>https://doi.org/10.3389/fsurg.2022.862322</u>

- [75] Khalid, N., Qayyum, A., Bilal, M., Al-Fuqaha, A., & Qadir, J. (2023). Privacy-preserving artificial intelligence in healthcare:
- 674 Techniques and applications. Computers in Biology and Medicine, 158, Article 106848.
- 675 <u>https://doi.org/10.1016/j.compbiomed.2023.106848</u>
- 676 [76] Murdoch, B. Privacy and artificial intelligence: challenges for protecting health information in a new era. BMC Med Ethics 22, 122
 677 (2021). https://doi.org/10.1186/s12910-021-00687-3
- 678
- 679
- 680
- 681
- 682
- 683
- 684
- 685
- 686





Tree-based models

Traditional ML Algorithms

Neural Networks

Prevalence of Performance Metrics in ML Studies for BSI Prediction





